arrow
V

Valter Gattei

fondazione cenci bolognetti
H指数:61
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

[18F] fdg-pet影像组学与液体活检的整合可改善新诊断的弥漫性大b细胞淋巴瘤的预后预测

Leukemia
IF13.4
2025-07-080
OAAI
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia

免疫球蛋白同种型内多样化测量的结果细化了慢性淋巴细胞白血病中IGHV突变状态的临床影响。

Leukemia
IF13.4
2025-06-180
OAAI
Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens

慢性淋巴细胞白血病中HERV-K和胚胎基因的表达及其与治疗方案的关系

2025-06-160
OAAI
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement
LEUKEMIA
IF13.4
2024-12-170
OAAI
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna

利用ctDNA对经典霍奇金淋巴瘤进行的全面遗传学研究

BLOOD
IF23.1
2024-11-050
PRE
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
LEUKEMIA
IF13.4
2024-08-141
OAAI
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-06-241
OAAI
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-03-154
OAAI
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort

Ibrutinib作为80岁以上慢性淋巴细胞白血病患者的一线治疗: 回顾性现实生活中的多中心意大利队列

2024-01-242
OAAI
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
2023-10-192
OA
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA